Integrated Analysis Identifies an Immune-Based Prognostic Signature for the Mesenchymal Identity in Gastric Cancer

Table 2

Univariate and multivariate analyses of immune signature and clinicopathological factors.

	Metavalidation cohorts
	Univariate		Multivariate
	HR (95% CI)		HR (95% CI)
Gender (male vs. female)	1.09 (0.90-1.33)	0.36	1.02 (0.75-1.39)	0.9
Stage (III & IV vs. I & II)	3.62 (2.64-4.96)	1.24-15	3.32 (2.32-4.75)	5.2-11
Histology (diffuse & others)	1.38 (1.03-1.84)	0.03	1.23 (0.91-1.66)	0.18
Immune signature (high vs. low risk)	1.76 (1.46-2.11)	1.34-09	1.93 (1.42-2.62)	2.5-05